Marienell Talla BSc , Nathan Best BSc , Abhinay Challa MD , Sruthy Balakumar BSc , Sergio Lopez-Tejero MD, PhD , Ella Huszti PhD , Eric Horlick MD , Rafael Alonso-Gonzalez MD, PhD , Lusine Abrahamyan MD, MPH, PhD
{"title":"Long-Term Outcomes of Fontan Patients With an Extracardiac Conduit: A Systematic Review and Meta-Analysis","authors":"Marienell Talla BSc , Nathan Best BSc , Abhinay Challa MD , Sruthy Balakumar BSc , Sergio Lopez-Tejero MD, PhD , Ella Huszti PhD , Eric Horlick MD , Rafael Alonso-Gonzalez MD, PhD , Lusine Abrahamyan MD, MPH, PhD","doi":"10.1016/j.cjca.2025.02.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although Fontan palliation improves survival, it poses a large burden of lifelong morbidity. In extracardiac Fontan (ECF) patients, for example, conduit stenosis developing over time has been associated with Fontan failure and other adverse outcomes. This systematic review, for the first time, synthesized existing data on various long-term outcomes of ECF patients, including change in conduit and associated outcomes.</div></div><div><h3>Methods</h3><div>We searched the Medline, Embase, and Cochrane indexes from inception to 2023 and included studies reporting separate results for ECF patients with a follow-up time of at least 3 years. Full-text studies were assessed for risk of bias. We summarised information on the study, patient characteristics, and outcomes narratively and with the use of descriptive tables. Meta-analysis was performed to calculate pooled incidence rates of adverse events.</div></div><div><h3>Results</h3><div>We included 61 full-text studies, with most studies published after 2009 (77.0%) and using a retrospective cohort design (76.2%). The pooled incidence rates per 100 person-years were for arrhythmia 1.8 (95% confidence interval [CI] 1.3-2.6), thrombotic events 0.2 (95% CI 0.1-0.4), protein-losing enteropathy 0.7 (95% CI 0.5-1.0), conduit obstruction 0.7 (95% CI 0.3-1.5), reoperation 1.9 (95% CI 1.1-3.4), and late death 0.3 (95% CI 0.2-0.5). The ranges of hemodynamic and exercise parameters and findings from studies reporting changes in conduit size and liver disease were reported.</div></div><div><h3>Conclusions</h3><div>Although many studies have largely focused on long-term survival, several other adverse outcomes require further research to develop consensus-based definitions and approaches for evaluations, especially as the ECF population ages. (PROSPERO: CRD42024533080)</div></div>","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":"41 6","pages":"Pages 1162-1171"},"PeriodicalIF":5.3000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0828282X25001278","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Although Fontan palliation improves survival, it poses a large burden of lifelong morbidity. In extracardiac Fontan (ECF) patients, for example, conduit stenosis developing over time has been associated with Fontan failure and other adverse outcomes. This systematic review, for the first time, synthesized existing data on various long-term outcomes of ECF patients, including change in conduit and associated outcomes.
Methods
We searched the Medline, Embase, and Cochrane indexes from inception to 2023 and included studies reporting separate results for ECF patients with a follow-up time of at least 3 years. Full-text studies were assessed for risk of bias. We summarised information on the study, patient characteristics, and outcomes narratively and with the use of descriptive tables. Meta-analysis was performed to calculate pooled incidence rates of adverse events.
Results
We included 61 full-text studies, with most studies published after 2009 (77.0%) and using a retrospective cohort design (76.2%). The pooled incidence rates per 100 person-years were for arrhythmia 1.8 (95% confidence interval [CI] 1.3-2.6), thrombotic events 0.2 (95% CI 0.1-0.4), protein-losing enteropathy 0.7 (95% CI 0.5-1.0), conduit obstruction 0.7 (95% CI 0.3-1.5), reoperation 1.9 (95% CI 1.1-3.4), and late death 0.3 (95% CI 0.2-0.5). The ranges of hemodynamic and exercise parameters and findings from studies reporting changes in conduit size and liver disease were reported.
Conclusions
Although many studies have largely focused on long-term survival, several other adverse outcomes require further research to develop consensus-based definitions and approaches for evaluations, especially as the ECF population ages. (PROSPERO: CRD42024533080)
期刊介绍:
The Canadian Journal of Cardiology (CJC) is the official journal of the Canadian Cardiovascular Society (CCS). The CJC is a vehicle for the international dissemination of new knowledge in cardiology and cardiovascular science, particularly serving as the major venue for Canadian cardiovascular medicine.